BMRN - バイオマリン・ファ―マシュ―ティカルズ （BioMarin Pharmaceutical Inc.）BMRNのニュース
Explosive growth on Hemophilia A Treatment Market 2021-2027: Global Companies like CSL Behring, Pfizer, Bayer, BioMarin, Genzyme, Chugai Pharma 2021/10/04 10:51:33 OpenPR
Overview of Global Hemophilia A Treatment Market: With an international Hemophilia A Treatment Market report, businesses will come to know current and future of Market outlook in the developed and emerging Markets. The report provides analysis of various perspectives of the
Hereditary Testing Market 2021-2027 | Latest COVID19 Impact Analysis | Know About Brand Players: Roche, Abbott, Amgen, Pfizer, BioMarin, Sanofi, Takeda 2021/09/28 10:30:58 OpenPR
Overview of Global Hereditary Testing Market: Todays businesses choose the market research report solution such as Hereditary Testing Market report because it lends a hand with the improved decision making and more revenue generation. The report also aids in prioritizing Market
Phenylketonuria (PKU) Market Research Report 2021 Challenges and General Business Research to 2027|Biomarin, Mead Johnson, Abbott, Nutricia, Dr. Schr 2021/09/14 09:21:57 OpenPR
The report titled Global Phenylketonuria (PKU) MARKET is one of the most comprehensive and important additions to market research studies. It offers detailed research and analysis of key aspects of the Phenylketonuria (PKU) market. The market analysts authoring this report
BioMarin upgraded by Stifel to Buy on potential FDA nod for dwarfism drug 2021/09/09 15:17:19 Seeking Alpha
Thursdays Top Analyst Upgrades and Downgrades: Baker Hughes, BioMarin, Cisco, Haliburton, Macys, Schlumberger, Sherwin-Williams and More 2021/09/09 12:55:27 24/7 Wall street
Exclusive Research Report On Hemophilia Treatment Market 2021. Major Players CSL Behring, Baxalta, Pfizer Inc, BioMarin, Bayer Healthcare, etc. 2021/07/07 11:30:41 Tramways Monthly
DataIntelo has released their new Hemophilia Treatment Market research report and forecasts for the industry for next eight years. The company predicts that by 2028, there will be a XX% increase in global demand and market will grow with a CAGR of XX%. With this forecast, the future of Hemophilia Treatment market looks bright. The []
BioMarin resubmits haemophilia A gene therapy to the EMA - PharmaTimes 2021/07/03 16:32:01 The Pharma Times
Company initially withdrew a marketing authorisation application for the gene therapy last year
BioMarin Announces 12 Presentations at the International Society on Thrombosis and Haemostasis (ISTH) 2021 Virtual Congress 2021/07/02 13:05:00 Investors Biomarin
Findings to be Presented from Ongoing Studies of Valoctocogene Roxaparvovec Represent Largest and Longest Development Program for any Gene Therapy in Hemophilia A
Canada: Plaintiff Cannot Amend Statement Of Claim More Than 45 Days After Receipt Of NOAs To Plead Infringement Of Further Patents - Smart & Biggar 2021/07/02 11:11:38 Mondaq
On May 5, 2021, the Federal Court dismissed a motion by Biomarin Pharmaceutical Inc (Biomarin) to amend its Statement of Claim to allege infringement of two patents that had not been asserted
Batten Disease Treatment Market (2021-2027) | Latest COVID19 Impact Analysis | Know About Brand Players: Abeona Therapeutics Inc., BioMarin Pharmaceutical Inc., CereSpir Inc., Evotec AG, Ionis Pharmaceuticals Inc., Mitochon Pharmaceuticals Inc., and Spark 2021/07/01 07:51:57 OpenPR
Precision Business Insights published a research report on "Batten Disease Treatment Market by Type of disease (Juvenile NCL (JNCL), Infantile NCL (INCL), Late infant NCL (LINCL), Adult NCL, Others), Treatment (Gene Therapy, Drug Therapy, Enzyme Therapy, Others), Distribution channel (Hospital
BioMarin''s gene therapy lead jumps ship to rival biotech Vedere Bio II 2021/06/22 12:17:21 FierceBiotech
BioMarin''s gene therapy lead jumps ship to rival biotech Vedere Bio II badams Tue, 06/22/2021 - 08:17
Is BioMarin Pharmaceutical Inc. (BMRN) A Good Stock To Buy? 2021/06/21 16:17:50 Yahoo Finance
Hedge funds and large money managers usually invest with a focus on the long-term horizon and, therefore, short-lived dips or bumps on the charts usually dont make them change their opinion towards a company. This time it may be different. The coronavirus pandemic destroyed the high correlations among major industries and asset classes. We are []
Aurinia Announces Addition of Dr. Brinda Balakrishnan to the Board of Directors 2021/06/14 10:05:00 Business Wire
VICTORIA, British Columbia--(BUSINESS WIRE)---- $AUPH--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (Aurinia or the Company) announced today the appointment of Dr. Brinda Balakrishnan, M.D., Ph.D., to the Companys Board of Directors effective June 14, 2021. Dr. Balakrishnan is Group Vice President, Corporate and Business Development of BioMarin Pharmaceutical Inc. (BioMarin), a global biotechnology company that develops and commercializes innovative therapies for patients with serious and li